Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: BIO Conference

Agenus, Inc. (AGEN) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Agenus is a biotechnology company engaged in developing treatments for cancers and infectious diseases. The company’s focus is on immunotherapeutic products based on strong platform technologies, with multiple product candidates advancing through the clinic, including a number of product candidates … Continue reading

Posted in BIO Conference | Leave a comment

Tonix Pharmaceuticals Holding Corp. (TNXP) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Tonix Pharmaceuticals Holding is focused on the development of innovative prescription medicines for challenging disorders of the central nervous system. Tonix targets conditions characterized by significant unmet medical need, inadequate existing treatments and high patient and physician dissatisfaction. The company’s … Continue reading

Posted in BIO Conference | Leave a comment

Palatin Technologies, Inc. (PTN) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Palatin Technologies is a biopharmaceutical company engaged in the development of targeted, receptor-specific peptide therapeutics for treating diseases that have significant unmet medical need but where there is also commercial potential. The company’s strategy involves developing products and then forming … Continue reading

Posted in BIO Conference | Leave a comment

Lexicon Pharmaceuticals, Inc. (LXRX) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Lexicon Pharmaceuticals is a biopharmaceutical company engaged in the discovery of breakthrough treatments for human disease. Currently, the company has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis. The company has identified … Continue reading

Posted in BIO Conference | Leave a comment

CEL-SCI Corp. (CVM) Starts Presentation at 15th Annual BIO CEO & Investor Conference

CEL-SCI is a biotechnology company engaged in research and development directed toward improving treatments for cancer and other diseases through utilization of the immune system – the body’s natural defense system. Multikine, the company’s lead investigational therapy, is being studied … Continue reading

Posted in BIO Conference | Leave a comment

Repros Therapeutics, Inc. (RPRX) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Repros Therapeutics is a development-stage biopharmaceutical company focused on developing oral small molecule drugs to address major unmet medical needs for male and female reproductive disorders. The company’s primary product candidate is Androxal, an orally active proprietary small molecule compound … Continue reading

Posted in BIO Conference | Leave a comment

GENFIT (ALGFT) Starts Presentation at 15th Annual BIO CEO & Investor Conference

GENFIT is a biopharmaceutical company at the forefront of drug discovery and development. The company’s focus is on the early diagnosis and preventive treatment of cardiometabolic and associated disorders. GENFIT’s mission is bringing therapeutic and diagnostic solutions to the pharmaceutical … Continue reading

Posted in BIO Conference | Leave a comment

NPS Pharmaceuticals, Inc. (NPSP) Starts Presentation at 15th Annual BIO CEO & Investor Conference

NPS Pharmaceuticals is a biopharmaceutical company engaged in bringing orphan products to patients who have rare disorders and few, if any, therapeutic options. The FDA-approved Gattex 0.05 mg/kg/d for subcutaneous injection is the company’s lead product. In addition to its … Continue reading

Posted in BIO Conference | Leave a comment

Furiex Pharmaceuticals, Inc. (FURX) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Furiex Pharmaceuticals is a drug development collaboration company using innovative clinical development design to accelerate and increase the value of drug development programs, cost-efficiently advancing them through the drug discovery and development process. The company’s drug development programs are designed … Continue reading

Posted in BIO Conference | Leave a comment

ReNeuron Group Plc. (RENE) Starts Presentation at 15th Annual BIO CEO & Investor Conference

ReNeuron Group is a clinical-stage stem cell leader primarily focused on developing novel stem cell therapies to target areas of important unmet or inadequately met medical need. The company has used its stem cell technologies to develop cell-based therapies for … Continue reading

Posted in BIO Conference | Leave a comment